OBJECTIVE: To assess the value of routine periodic physical examination in the follow-up of ovarian (OvC) and primary peritoneal carcinoma (PPC) patients with pretreatment elevated CA125 levels. METHODS: Included were patients who had a pretreatment serum CA125 level above normal limits, had completed initial treatment, were in complete clinical remission on completion of the initial treatment and routinely attended the gynecologic oncology outpatient clinic. Recurrence was diagnosed when at least one of the following criteria was abnormal: symptoms, physical examination or elevated serum CA125 levels. RESULTS: Of 69 patients, a recurrence was diagnosed in 43. Abnormal physical examination for diagnosis of recurrence yielded a sensitivity rate of only 34.9%. The diagnosis of recurrence was based on an abnormal physical examination alone in 2 (4.6%) patients. CONCLUSION: In OvC and PPC patients with elevated pretreatment CA125 levels, physical examination has a limited impact on the diagnosis of recurrence.
OBJECTIVE: To assess the value of routine periodic physical examination in the follow-up of ovarian (OvC) and primary peritoneal carcinoma (PPC) patients with pretreatment elevated CA125 levels. METHODS: Included were patients who had a pretreatment serum CA125 level above normal limits, had completed initial treatment, were in complete clinical remission on completion of the initial treatment and routinely attended the gynecologic oncology outpatient clinic. Recurrence was diagnosed when at least one of the following criteria was abnormal: symptoms, physical examination or elevated serum CA125 levels. RESULTS: Of 69 patients, a recurrence was diagnosed in 43. Abnormal physical examination for diagnosis of recurrence yielded a sensitivity rate of only 34.9%. The diagnosis of recurrence was based on an abnormal physical examination alone in 2 (4.6%) patients. CONCLUSION: In OvC and PPC patients with elevated pretreatment CA125 levels, physical examination has a limited impact on the diagnosis of recurrence.
Authors: Jacqueline Feinberg; Karen Carthew; Emily Webster; Kaity Chang; Nita McNeil; Dennis S Chi; Kara Long Roche; Ginger Gardner; Oliver Zivanovic; Yukio Sonoda Journal: Int J Gynecol Cancer Date: 2021-12-29 Impact factor: 3.437
Authors: N B Rettenmaier; C R Rettenmaier; T Wojciechowski; L N Abaid; J V Brown; J P Micha; B H Goldstein Journal: Br J Cancer Date: 2010-11-02 Impact factor: 7.640
Authors: Charlotte S Marcus; G Larry Maxwell; Kathleen M Darcy; Chad A Hamilton; William P McGuire Journal: J Cancer Date: 2014-01-01 Impact factor: 4.207